Risk factors

Here’s what we’ve learned from 30 years of DCCT/EDIC

In an ADS plenary session Professor Dr Ian de Boer from the University of Washington in Seattle took delegates through what we’ve learned about diabetes related kidney disease from the landmark DCCT and EDIC studies.  As you’d expect there’s a lot of knowledge gained from over 30 years of analysis. Here’s a whistle stop tour of Professor de Boer’s summary:

  • The long term renal benefits of intensive therapy remain visible for 18 years (otherwise known as ‘metabolic memory’) (access study here).
  • Intensive diabetes therapy reduces the risk of reduced GFR
  • The long-term risk of an impaired GFR was significantly lower among people treated early in the course of type 1 diabetes with intensive diabetes therapy compared to those treated with conventional diabetes therapy (access study here)
  • Intensive therapy reduces the long term risk of hypertension (access study here)
  • Early intensive therapy alters the clinical course of albuminuria (access study here)
  • Urine albumin excretion progresses and regresses over time – not everyone with microalbuminuria progresses (access study here)
  • Albumin is a strong risk factor for GFR loss (access study here)
  • Reduced GFR can develop without microalbuminuria ( access study here)
  • Albumin is also a strong risk factor for cardiovascular disease (access study here)
  • Obesity is associated with albuminuria but not GFR loss (access study here)
  • Lower 25 (OH)  D levels are associated with incident albuminuria (access study here).

Already a member?

Login to keep reading.

Email me a login link

© 2022 the limbic